Navigation Links
Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A study that aimed to understand how the cancer drug everolimus helps overcome the resistance breast cancers can develop to trastuzumab has left researchers contemplating a puzzle.

The study showed a statistically non-significant benefit in clinical response rates for some patients with early breast cancer when everolimus was added to treatment with trastuzumab. Yet the results suggest this benefit is achieved independently of the molecular pathways researchers expected would be involved.

Prof Mario Campone, Principal Investigator at Institut Cancerologie de l'Ouest in Nantes, France, presented the findings at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium. The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

"As more targeted cancer drugs are developed, the challenge is to identify which patients will benefit from individual agents," Prof Campone said. "One of the objectives of this study was to determine molecular biomarkers that predict whether a patient's cancer is sensitive to the combination of everolimus and trastuzumab compared to trastuzumab alone."

Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Many patients who initially respond to trastuzumab develop resistance.

In preclinical studies, everolimus, an oral inhibitor of an important molecule called mammalian target of rapamycin (mTOR), has demonstrated an ability to reverse trastuzumab resistance. However, the mechanisms of action involved in the reversion of trastuzumab resistance are not completely understood.

"Resistance to trastuzumab may result from several molecular alterations occurring at different levels of the downstream effectors in the PI3K/AKT pathway, all of them resulting in maintenance of signal transduction," Prof Campone explains. "Therefore, using everolimus to inhibit mTOR, a major downs
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study reveals magnitude of variation in gene expression measurements within breast cancers
2. Study opens new prospects for developing new targeted therapies for breast cancer
3. Breast cancer heterogeneity no barrier to predictive testing, study shows
4. BUSM study shows positive impact of mind-body course on well-being of medical students
5. Study finds possible alternative to bariatric weight loss surgery
6. Zebrafish study suggests that vitamin B2 (riboflavin) is an antidote to cyanide poisoning
7. Study examines effects of genetic variants for infants with neonatal abstinence syndrome
8. University of Houston engineering professor awarded grant to study melanoma treatment
9. Monoclonal Antibody with Xencors High ADCC Fc Technology Enters Phase 2 Study in B-cell Acute Lymphoblastic Leukemia
10. BUSM study reveals novel mechanism by which UVA contributes to photoaging of skin
11. Study led by NUS scientists reveals escalating cost of forest conservation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/23/2015)... Mass , March 23, 2015 SoundView Technology ... of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView was ... user feedback on their experience with the Wocket in multiple ... at CVS, Whole Foods and other retailers, making both debit ... Kris Tuttle also says, "If the company meets their ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... simulations, researchers at the University of Illinois have demonstrated a ... forth through a nanopore capacitor in a semiconductor chip. The ... genomes quickly and affordably., Being able to sequence a human ... insurance companies are willing to pay) could open a new ...
... BOWLING GREEN, O.Bowling Green State University biology undergraduates will ... genomics while they learn. The University has been selected ... new Microbial Genome Annotation research program through the U.S. ... Analysis of the genomes of microorganisms is an important ...
... Investigators at the University of Rochester Medical Center have ... of hope for children with Batten disease a ... robs them of their abilities to see, reason and ... The study, highlighted in the January edition of ...
Cached Biology News:New technique could dramatically lower costs of DNA sequencing 2BGSU undergraduates to pilot groundbreaking genome project 2BGSU undergraduates to pilot groundbreaking genome project 3Research unveils new hope for deadly childhood disease 2
(Date:4/16/2015)... (PRWEB) April 16, 2015 Capillus, ... distribution and physician network in Europe and Asia. ... has appointed Fernando Bermúdez, former Business Development Director ... An industry veteran, Mr. Bermúdez’s professional achievements include ... in Spain, while also penetrating the Portuguese marketplace ...
(Date:4/16/2015)... 16, 2015 OncoTAb, Inc., ... (UNC Charlotte) spin-out company, announced today the appointment ... M.D., as Chief Operating Officer (COO). Cooper brings ... in developing clinical diagnostic and biotechnology platforms in ... , Cooper’s extensive career transcends the field of ...
(Date:4/16/2015)... , April 16, 2015 /CNW/ - Bioenterprise Corporation is pleased ... office in Charlottetown , PEI.  Bioenterprise ... Edward Island ADAPT Council for the commercialization of agricultural ... to working with PEI ADAPT.  They have been at ... than a decade," explains Dave Smardon , President ...
(Date:4/16/2015)... SAN DIEGO , April 16, 2015 ... company dedicated to improving cancer surgeries, announced today that ... lead fluorescent cancer illuminator, AVB-620, in women with primary, ... trial, the company also welcomed the addition of ... affairs. The open label, dose escalation study ...
Breaking Biology Technology:Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2OncoTAb Names Dr. David L. Cooper as COO 2Bioenterprise Corporation Expands into the Maritimes 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3
... Technologies, Inc.,(OTC Bulletin Board: AVXT) (the "Company") today ... bridge loan financing pursuant to a Convertible Note,and ... to Convertible,Note and Warrant Purchase Agreement (collectively the ... promissory notes,(the "Notes") in the aggregate principal amount ...
... SAN DIEGO, Oct. 30 Anadys Pharmaceuticals,Inc. (Nasdaq: ... ANA773 in,patients chronically infected with hepatitis C virus (HCV) ... ANA773 in both healthy volunteers and,HCV patients. ANA773 is ... of the study, patients in the first cohort will ...
... (Nasdaq:,CEPH) today announced that its Analyst Day in New ... be webcast live on the investor relations section of,its ... will review the company,s business,strategy, marketing plan and research ... November 5, 2008 beginning at,approximately 12:30 p.m. EST and ...
Cached Biology Technology:AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing 2Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 2Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 3Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 4Anadys Pharmaceuticals Commences Dosing ANA773 in Hepatitis C Patients 5Cephalon, Inc. to Webcast Analyst Day 2Cephalon, Inc. to Webcast Analyst Day 3
... 75 x 25 mm; approximately 1 ... immunohistochemistry of paraffin-embedded sections, ... markings will not rub off ... precleaned, store ...
Complete cell culture media with cytokines...
HAS1 (C-14)...
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: